UGUP17050 / Deepak Cisplatin Pilot IIT / Deepak Sahasrabudhe
Basic Study Information
Purpose:Location: Wilmot Cancer Institute
It is hypothesized that treatment with cisplatin will reverse emerging refractoriness
to enzalutimide in patients with CRPC by affecting AR function.
Lead Researcher (Principal Investigator)
Deepak Sahasrabudhe, MD
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search